Natco Pharma Ltd (NATCOPHARM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Natco Pharma Ltd on NSE and BSE, with an AI summary of each filing.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 04, 2026 for V C Nannapaneni
Encumbered Shares - Invocation / Release · 04 Nov 2026, 9:01 pm
Natco Pharma Promoter Pledges 0.47% Stake for Rights Issue Natco Pharma promoter V.C. Nannapaneni created a pledge on 8,50,000 equity shares (face value ₹2 each), representing 0.47% of the total share capital, on 9th Oct'26 in favor of Bajaj Financial Securities Limited. The pledge was executed to fund participation in the company's rights issue. Prior to this event, Nannapaneni held 2,80,45,905 shares (15.66% stake) with zero encumbrances. Post-transaction, total encumbered holding stands at 8,50,000 shares (0.47% of total capital), as per revised disclosures submitted on 4th Nov'26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkaiah Chowdary Nannapaneni
Acquisition/ Disposal of Shares · 30 Oct 2026, 4:12 pm
Natco Pharma Promoters Acquire Equity Shares via Rights Issue Allotment Natco Pharma Limited disclosed share acquisitions by promoter and promoter group entities pursuant to a rights issue allotment on 26th Oct'26. Consequently, the company's total paid-up equity capital increased from 17,91,09,870 shares to 19,61,67,952 shares of Rs. 2 each. Key promoter allotments included Time Cap Pharma Labs (9,33,333 shares; 9.23% post-issue stake), Venkaiah Chowdary Nannapaneni (5,86,666 shares; 14.60%), Neelima Sita Nannapaneni (2,55,387 shares), Natsoft Information Systems (2,40,000 shares; 8.17%), and Venkata Satya Swathi Kantamani (61,333 shares; 8.15%), among other participating group trusts and entities.
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....
Intimation · 13 Nov 2026, 5:30 am
Natco Pharma Board to Consider Q2 Results and Second Interim Dividend Natco Pharma Limited's Board of Directors is scheduled to meet on 13th Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the board will evaluate the declaration of a second interim dividend for FY27. In compliance with insider trading regulations, the trading window for dealing in company securities remains closed for designated persons and insiders from 30th Oct'26 through 15th Nov'26, re-opening on 16th Nov'26.
NATCO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.
Intimation · 13 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and dividend
Intimation · 13 Nov 2026, 5:30 am
Natco Pharma Limited has informed the Exchange regarding the approval of allotment of 17058082 Equity shares pursuant to Rights Issue by the Fund-Raising Committee at its meeting held on October 23, 2026
Others (Uncategorized) · 24 Oct 2026, 2:35 am
Outcome of the Fund-raising Committee meeting approving the allotment of 17058082 Equity shares
Others (Uncategorized) · 24 Oct 2026, 2:35 am
Natco Pharma Approves Allotment of 1.71 Crore Equity Shares via Rights Issue Natco Pharma Limited's Fund Raising Committee approved the allotment of 1,70,58,082 equity shares on 23rd Oct'26 pursuant to its rights issue. The shares were allotted at an issue price of ₹750 per share, including a premium of ₹748 per share against a face value of ₹2. Consequently, the company's paid-up equity share capital expanded from ₹35,82,19,740 (17,91,09,870 shares) to ₹39,23,35,904 comprising 19,61,67,952 fully paid-up equity shares.
Intimation of closure of the Issue period of the Rights Issue of NATCO Pharma Limited (the "Company")
Rights Issue · 22 Oct 2026, 6:55 pm
NATCO Pharma Announces Closure of ₹12,794 Million Rights Issue NATCO Pharma Limited confirmed the closure of its Rights Issue on 22nd Oct'26, which originally opened on 12th Oct'26. The issue comprised equity shares of face value ₹2 each offered at a cash price of ₹750 per share, raising an aggregate amount of up to ₹12,794 million. The issue terms were previously approved by the Board of Directors on 25th Sep'26 in compliance with SEBI ICDR Regulations and the Companies Act.
Natco Pharma announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market
Press Release · 19 Oct 2026, 7:55 pm
Natco Pharma Launches Generic Carboplatin Injection in the US Market NATCO Pharma Limited announced on 19th Oct'26 that its US subsidiary, NATCO Pharma USA LLC, has launched Carboplatin Injection (generic Paraplatin) in the US market in manufacturing collaboration with Chennai-based Teyro Labs Pvt Ltd. The oncology product addresses a critical US market shortage and is indicated for advanced ovarian carcinoma treatment. According to industry sales data, Carboplatin Injection generated estimated annual US sales of USD 27.8 million for the 12 months ending Jun'26.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 12, 2026 for V C Nannapaneni
Encumbered Shares - Invocation / Release · 13 Oct 2026, 3:58 pm
Natco Pharma Promoter V.C. Nannapaneni Pledges 8.5 Lakh Equity Shares Natco Pharma Limited promoter V.C. Nannapaneni disclosed the creation of a pledge on 8,50,000 equity shares (face value Rs. 2 each), representing 0.47% of the company's total share capital, in favor of Bajaj Financial Securities Limited on 9th Oct'26. Prior to this event, the promoter held 2,80,45,905 shares (15.66% stake) with zero encumbrance. Post-transaction, total encumbered shares stand at 8,50,000, representing 0.47% of total share capital.
Evoting Results along with Scrutinizer Report for the 43rd Annual General Meeting held on 30/09/2026
Annual General Meeting · 30 Sept 2026, 11:11 pm
Proceedings of the 43rd Annual General Meting
Annual General Meeting · 30 Sept 2026, 6:14 pm
NATCO Pharma 43rd AGM Key Proceedings and Capital Raise Approval NATCO Pharma held its 43rd Annual General Meeting on 30th Sep'26, considering key ordinary and special resolutions. The company sought approval to raise funds up to ₹2,000 crore in one or more tranches via preferential issue, rights issue, private placement, QIP, or other permissible modes. Shareholders also considered the adoption of FY25-26 audited financial statements, the confirmation of three interim dividends totaling ₹5.00 per share paid for FY25-26, and the re-appointment of Director P.S.R.K. Prasad. Combined e-voting results will be declared within two working days.
Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue
Others (Uncategorized) · 29 Sept 2026, 2:22 am
Natco Pharma Limited has informed the Exchange regarding Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue
Others (Uncategorized) · 29 Sept 2026, 2:22 am
Press Release and disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Press Release · 28 Sept 2026, 8:28 pm
Natco Pharma Increases Investment in eGenesis to US$16.70 Million Natco Pharma has increased its planned investment in US-based biotechnology firm eGenesis, Inc. from US$14.00 million to US$16.70 million via convertible promissory notes carrying an 8% annual interest rate. The transaction comprises US$13.70 million via Natco Pharma (Canada) Inc. and US$3.00 million via Natco Pharma USA LLC, with completion targeted by 31st Oct'26. Following an earlier US$8.00 million investment in 2024, Natco's total commitment will rise to US$24.70 million, backing eGenesis's multiplex gene-editing platform for cross-species organ transplantation.
Intimation of Record Date for Rights Issue
Rights Issue · 25 Sept 2026, 4:55 pm
Natco Pharma Fixes Record Date for Rights Issue on 1st Oct'26 Natco Pharma Limited announced that its Board of Directors has fixed Thursday, 1st Oct'26, as the record date for its upcoming Rights Issue of equity shares. The record date will determine eligible shareholders entitled to receive Rights Entitlements under the issue, in compliance with Regulation 42 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Out come of Board Meeting
Others (Uncategorized) · 25 Sept 2026, 4:49 pm
Natco Pharma Board Approves ₹1,279.36 Crore Rights Issue Natco Pharma's board approved a Rights Issue to raise up to ₹1,279.36 crore through the issuance of 1,70,58,082 equity shares of face value ₹2 each at ₹750 per share (including a ₹748 premium). The entitlement ratio is set at 2 rights shares for every 21 shares held as of the record date on 1st Oct'26. The issue opens on 12th Oct'26 and closes on 22nd Oct'26, with on-market renunciation from 12th Oct'26 to 16th Oct'26. Outstanding equity shares will expand from 17,91,09,870 to 19,61,67,952 post-issue.
Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : ....
Outcome · 25 Sept 2026, 4:48 pm
Natco Pharma Approves ₹1,279.36 Crore Rights Issue Natco Pharma's board approved a rights issue of up to 1,70,58,082 equity shares (face value ₹2) at ₹750 per share (₹748 premium), raising up to ₹12,79.36 crore. The entitlement ratio is set at 2:21 (2 rights shares for every 21 shares held) with a record date of 1st Oct'26. The issue opens on 12th Oct'26 and closes on 22nd Oct'26, with on-market renunciation from 12th Oct'26 to 16th Oct'26. Outstanding equity will expand from 17,91,09,870 to 19,61,67,952 shares post-issue upon full subscription.
NATCO PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 25-Sep-2026 to consider Fund raising.
Intimation · 22 Sept 2026, 11:31 pm
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2026 ,inter alia, to consider and approve to consider, discuss and decide ....
Intimation · 22 Sept 2026, 11:26 pm
Natco Pharma Board to Finalize Terms for ₹1,300 Crore Rights Issue Natco Pharma Limited announced that its Board of Directors will meet on 25th Sep'26 to determine key terms for its proposed rights issue of up to ₹1,300 crore (face value ₹2 per share), previously approved on 9th Sep'26. The meeting will decide the issue price, payment mechanism, rights entitlement ratio, record date, and issue timing. Consequently, the trading window for designated persons and insiders will remain closed from 23rd Sep'26 until 48 hours post the outcome's disclosure.
Receipt of In-principal approval for Rights Issue of Equity Shares
Rights Issue · 22 Sept 2026, 4:14 am
Natco Pharma Secures In-Principle Stock Exchange Approvals for Rights Issue Natco Pharma Limited received in-principle approval from both the National Stock Exchange of India and BSE Limited on 21st Sep'26 for its proposed rights issue of fully paid-up equity shares. This regulatory clearance represents a key procedural milestone, enabling the company to advance its equity capital-raising process.
Draft letter of Offer
Others (Uncategorized) · 09 Sept 2026, 11:21 pm
Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026.
Outcome · 09 Sept 2026, 5:23 pm
Outcome of Board Meeting
Outcome · 09 Sept 2026, 5:17 pm
Natco Pharma Approves Rights Issue Up to ₹1,300 Crore and Scheme Modifications Natco Pharma's Board approved a rights issue of equity shares (face value ₹2 each) aggregating up to ₹1,300 crore on 9th Sep'26, alongside approving the Draft Letter of Offer and forming a Fund-Raising Committee. The capital expansion will alter the company's shareholding pattern, prompting corresponding revisions to its demerger scheme with Natco Crop Health Sciences to maintain the proposed share swap ratio. Revised scheme filings will be submitted to stock exchanges following the completion of the rights issue prior to NCLT filing.
Notice of 43rd Annual General Meeting of the Company scheduled to be held on Wednesday, the September 30, 2026 at 11:00 AM (IST)
Annual General Meeting · 05 Sept 2026, 2:29 am